通过工程化细胞外囊泡靶向严重急性呼吸综合征冠状病毒2的充分理由。
Good reasons for targeting SARS-CoV-2 by engineered extracellular vesicles.
作者信息
de Marco Ario, Barile Lucio
机构信息
Laboratory for Environmental and Life Sciences, University of Nova Gorica, Nova Gorica, Slovenia.
Laboratory for Cardiovascular Theranostics, Istituto Cardiocentro Ticino, Ente Ospedaliero Cantonale and Faculty of Biomedical Sciences, Università Svizzera italiana, Lugano, Switzerland.
出版信息
Mol Ther Methods Clin Dev. 2022 Mar 9;25:41-42. doi: 10.1016/j.omtm.2022.02.003. eCollection 2022 Jun 9.
SARS-CoV-2 entry is mediated by binding of the spike protein (S) to the surface receptor ACE2. Engineered extracellular vesicles (EVs) exposing specific antibody fragments, namely nanobodies, are efficient decoys for S protein. EVs may act as a multifunctional vector to reduce SARS-CoV-2 infectivity and simultaneously modulate the inflammatory microenvironment in COVID-19 patients.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的进入是由刺突蛋白（S）与表面受体血管紧张素转换酶2（ACE2）结合介导的。暴露特定抗体片段（即纳米抗体）的工程化细胞外囊泡（EVs）是S蛋白的有效诱饵。细胞外囊泡可作为多功能载体，降低SARS-CoV-2的感染性，并同时调节新冠肺炎患者的炎症微环境。
Zotero 插件